Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
On September 30, 2022, Pyxis Oncology (Nasdaq: PYXS) announced the grant of restricted stock units for 213,030 shares and stock options for 266,290 shares to 17 newly hired employees under its 2022 Inducement Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On September 30, 2022, Pyxis Oncology (Nasdaq: PYXS) announced the grant of restricted stock units for 213,030 shares and stock options for 266,290 shares to 17 newly hired employees under its 2022 Inducement Plan. These awards are part of a strategy to attract talent and are in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term with an exercise price of $1.97. The vesting schedule includes 25% vesting on the first anniversary, with the balance vesting monthly over the following three years, contingent on continued employment.
Positive
- Granting stock options and restricted stock units indicates a strong commitment to attracting top talent.
- The exercise price of $1.97 aligns with the company's current stock valuation on the grant date, potentially benefitting employees.
Negative
- None.
Details
News Market Reaction – PYXS
The recorded move for PYXS in the trading session of this news was +1.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a diversified oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients, reported on September 30, 2022 that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 213,030 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 266,290 shares of Pyxis Oncology’s common stock to seventeen newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of September 30, 2022, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4).
The restricted stock units and stock options vest over four years, with
Pyxis Oncology is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is an oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. By leveraging our fully integrated research, development and commercial capabilities, our expert team is efficiently building a diversified portfolio of next-generation therapeutics. Pyxis Oncology’s therapeutic candidates are designed to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. Since its launch in 2019, Pyxis Oncology has developed a broad portfolio of novel antibody-drug conjugate, or ADC, immuno-oncology, or IO, product candidates, and monoclonal antibody, or mAb, preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. To learn more about Pyxis Oncology, visit www.pyxisoncology.com.
Pyxis Oncology Contact
Pamela Connealy
Chief Financial Officer
(617) 453-3596
ir@pyxisoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.